Sub-Anesthetic Ketamine in Patients with Respiratory Infections
Sub-anesthetic ketamine can be safely used in patients with active respiratory infections, as the evidence demonstrates no increased risk of respiratory adverse events when ketamine is used as a single agent, though caution is warranted if combining with benzodiazepines or dexmedetomidine.
Key Safety Evidence
The most robust recent data from a 2025 multicenter study of 38,910 pediatric ketamine sedations found that upper respiratory infection (URI) was only a significant risk factor when ketamine was combined with benzodiazepines or dexmedetomidine 1. When ketamine was used as a single agent or primary sedative, URI did not independently increase the risk of critical adverse events.
This finding is corroborated by a 2025 prospective cohort study of 6,292 children in emergency departments, which found no increased risk of respiratory adverse events (adjusted OR 1.00,95% CI 0.78-1.29), serious respiratory adverse events (adjusted OR 0.53,95% CI 0.18-1.58), or serious respiratory interventions (adjusted OR 1.08,95% CI 0.68-1.71) in children with URI undergoing procedural sedation 2.
Pharmacologic Basis for Safety
The FDA label and pharmacologic data explain why ketamine maintains respiratory safety even in the setting of respiratory infections 3:
- Ketamine is a potent bronchodilator, making it particularly suitable for patients at high risk for bronchospasm
- Preserves pharyngeal-laryngeal reflexes during dissociative sedation
- Produces only occasional transient and minimal respiratory depression
- The cardiovascular stimulation from indirect sympathomimetic activity helps maintain hemodynamic stability
Risk Stratification Algorithm
Low Risk (Ketamine Alone):
- URI present
- No adjunctive benzodiazepines or dexmedetomidine
- No opioid co-administration
- Proceed with standard ketamine dosing
Moderate Risk (Requires Enhanced Monitoring):
- URI + benzodiazepines or dexmedetomidine co-administration 1
- URI + opioid co-administration 1
- Age <6 months or >10 years with URI 1
- Consider avoiding adjunctive sedatives or using lower doses with closer monitoring
Contraindications (Per FDA Label):
The FDA label does not list respiratory infection as a contraindication 3. However, monitor for:
- Laryngospasm (rare but reported)
- Respiratory depression with rapid IV administration of high doses
- Airway obstruction
Practical Recommendations
For patients with active respiratory infections:
Use ketamine as a single agent when possible (0.15-0.30 mg/kg IV for analgesia; 1-2 mg/kg IV for sedation) 4
Avoid or minimize benzodiazepine/dexmedetomidine co-administration in URI patients, as this combination specifically increases risk 1
Avoid opioid co-administration when feasible, as this independently increases adverse event risk 1
Administer slowly - the FDA label emphasizes that respiratory depression occurs primarily with rapid IV administration of high doses 3
Maintain standard monitoring - the 2018 ASA guidelines recommend continuous monitoring regardless of URI status 5
Overall Safety Profile
The critical care medicine guidelines support ketamine use with very low quality evidence showing reduced opioid consumption without increased side effects (nausea, hallucinations, hypoventilation) 6. In the largest ketamine safety study, critical adverse events occurred in only 0.04% (1 per 2,594 sedations) with no deaths or permanent adverse outcomes 1.
A 2026 systematic review of 58,752 pediatric ketamine sedations found sentinel outcomes (intubation, aspiration, chest compressions) in only 0.0041% of cases, with URI showing only modest effect magnitude when present 7.
Common Pitfall to Avoid
The critical error is reflexively adding benzodiazepines to "prevent" emergence reactions in URI patients - this combination specifically increases respiratory risk 1. If emergence phenomena are a concern, benzodiazepines can be given reactively during recovery rather than prophylactically, or avoided entirely as emergence reactions are generally self-limited.